70 related articles for article (PubMed ID: 12592363)
1. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling.
Lee YF; John M; Edwards S; Clark J; Flohr P; Maillard K; Edema M; Baker L; Mangham DC; Grimer R; Wooster R; Thomas JM; Fisher C; Judson I; Cooper CS
Br J Cancer; 2003 Feb; 88(4):510-5. PubMed ID: 12592363
[TBL] [Abstract][Full Text] [Related]
2. Expression of smooth muscle markers in so called malignant fibrous histiocytomas.
Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y
J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549
[TBL] [Abstract][Full Text] [Related]
3. Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes.
Li S; Liu Q; Zhou H; Lu H; Wang X
J Transl Med; 2022 Jan; 20(1):48. PubMed ID: 35093080
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Targets in Synovial Sarcoma: A Mini-Review.
Hale R; Sandakly S; Shipley J; Walters Z
Front Oncol; 2019; 9():1078. PubMed ID: 31681608
[TBL] [Abstract][Full Text] [Related]
5. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.
Stefano S; Giovanni S
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31416195
[TBL] [Abstract][Full Text] [Related]
6. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.
Widemann BC; Italiano A
J Clin Oncol; 2018 Jan; 36(2):160-167. PubMed ID: 29220302
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance.
Lee YF; Roe T; Mangham DC; Fisher C; Grimer RJ; Judson I
Br J Cancer; 2016 Oct; 115(8):1000-1007. PubMed ID: 27607470
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in the pathobiology of sarcomas.
Sarver AE; Subramanian S
Lab Invest; 2015 Sep; 95(9):987-94. PubMed ID: 26121318
[TBL] [Abstract][Full Text] [Related]
9. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.
Demicco EG; Boland GM; Brewer Savannah KJ; Lusby K; Young ED; Ingram D; Watson KL; Bailey M; Guo X; Hornick JL; van de Rijn M; Wang WL; Torres KE; Lev D; Lazar AJ
Histopathology; 2015 Apr; 66(5):627-38. PubMed ID: 24889065
[TBL] [Abstract][Full Text] [Related]
10. Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review.
Li L; Schuster IP; Jacob R; Hupart KH; Gotlieb V
Springerplus; 2013; 2():536. PubMed ID: 24255838
[TBL] [Abstract][Full Text] [Related]
11. Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.
Silveira SM; Villacis RA; Marchi FA; Barros Filho Mde C; Drigo SA; Neto CS; Lopes A; da Cunha IW; Rogatto SR
PLoS One; 2013; 8(6):e67643. PubMed ID: 23825676
[TBL] [Abstract][Full Text] [Related]
12. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
Pennacchioli E; Tosti G; Barberis M; De Pas TM; Verrecchia F; Menicanti C; Testori A; Mazzarol G
Clin Exp Metastasis; 2012 Oct; 29(7):757-73. PubMed ID: 22699363
[TBL] [Abstract][Full Text] [Related]
13. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.
Przybyl J; Jurkowska M; Rutkowski P; Debiec-Rychter M; Siedlecki JA
Sarcoma; 2012; 2012():249219. PubMed ID: 22550415
[TBL] [Abstract][Full Text] [Related]
14. [Sarcoma gene signatures].
Chibon F; Coindre JM
Pathologe; 2011 Feb; 32(1):32-9. PubMed ID: 21287318
[TBL] [Abstract][Full Text] [Related]
15. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
Chibon F; Lagarde P; Salas S; Pérot G; Brouste V; Tirode F; Lucchesi C; de Reynies A; Kauffmann A; Bui B; Terrier P; Bonvalot S; Le Cesne A; Vince-Ranchère D; Blay JY; Collin F; Guillou L; Leroux A; Coindre JM; Aurias A
Nat Med; 2010 Jul; 16(7):781-7. PubMed ID: 20581836
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers.
Beck AH; West RB; van de Rijn M
Virchows Arch; 2010 Feb; 456(2):141-51. PubMed ID: 19412622
[TBL] [Abstract][Full Text] [Related]
17. The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.
Barco R; Garcia CB; Eid JE
PLoS One; 2009; 4(4):e5060. PubMed ID: 19337376
[TBL] [Abstract][Full Text] [Related]
18. Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.
Daigeler A; Klein-Hitpass L; Stricker I; Müller O; Kuhnen C; Chromik AM; Steinstraesser L; Goertz O; Steinau HU; Lehnhardt M
Langenbecks Arch Surg; 2010 Mar; 395(3):261-75. PubMed ID: 19159951
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic sarcoma signatures.
Davicioni E; Wai DH; Anderson MJ
Mol Diagn Ther; 2008; 12(6):359-74. PubMed ID: 19035623
[TBL] [Abstract][Full Text] [Related]
20. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.
Lehnhardt M; Daigeler A; Homann HH; Schwaiberger V; Goertz O; Kuhnen C; Steinau HU
Langenbecks Arch Surg; 2009 Mar; 394(2):313-20. PubMed ID: 18584203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
